ZIOPHARM Oncology (ZIOP) Rating Reiterated by Zacks Investment Research

Zacks Investment Research reiterated their hold rating on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a report published on Saturday morning.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

A number of other analysts also recently weighed in on ZIOP. ValuEngine downgraded ZIOPHARM Oncology from a hold rating to a sell rating in a research note on Friday, September 15th. HC Wainwright restated a buy rating and issued a $9.50 price target on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Raymond James Financial restated a hold rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Finally, BidaskClub upgraded ZIOPHARM Oncology from a strong sell rating to a sell rating in a research note on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. ZIOPHARM Oncology has a consensus rating of Hold and a consensus price target of $12.67.

ZIOPHARM Oncology (NASDAQ ZIOP) traded up $0.10 during trading on Friday, hitting $4.30. The company had a trading volume of 481,025 shares, compared to its average volume of 1,845,760. ZIOPHARM Oncology has a 12-month low of $3.77 and a 12-month high of $7.88. The stock has a market capitalization of $612.10, a P/E ratio of -8.27 and a beta of 1.44.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same quarter last year, the firm earned ($0.11) earnings per share. The firm’s quarterly revenue was up .0% compared to the same quarter last year. research analysts predict that ZIOPHARM Oncology will post -0.54 earnings per share for the current fiscal year.

In other news, CEO Laurence James Neil Cooper bought 6,440 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the completion of the transaction, the chief executive officer now owns 1,083,731 shares in the company, valued at $5,071,861.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.40% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC purchased a new stake in ZIOPHARM Oncology during the third quarter worth $145,000. Belpointe Asset Management LLC purchased a new stake in ZIOPHARM Oncology during the third quarter worth $746,000. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of ZIOPHARM Oncology by 127.5% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,896 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 14,513 shares in the last quarter. Chevy Chase Trust Holdings Inc. purchased a new stake in shares of ZIOPHARM Oncology in the third quarter valued at $104,000. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of ZIOPHARM Oncology by 6.6% in the third quarter. Schwab Charles Investment Management Inc. now owns 618,589 shares of the biotechnology company’s stock valued at $3,799,000 after acquiring an additional 38,440 shares in the last quarter. Institutional investors own 40.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://weekherald.com/2018/01/17/ziopharm-oncology-ziop-rating-reiterated-by-zacks-investment-research.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply